Ruxolitinib (INCB018424) in Subjects With Primary Myelofibrosis, Post Essential Thrombocythemia-myelofibrosis and Post Polycythemia Vera-myelofibrosis

Study Status

Open to Enrollment

Study Description

Full protocol title: An Open Label Assessment of Safety and Efficacy of Ruxolitinib (INCB018424) in Subjects With Primary Myelofibrosis (PMF), Post Essential Thrombocythemia-myelofibrosis (PPV-MF) and Post Polycythemia Vera-myelofibrosis (PET-MF) Who Have Platelet Counts of 50 x 10^9/L to 100 x 10^9/L

This clinical trial is for people diagnosed with Primary Myelofibrosis, Post Essential Thrombocythemia-Myelofibrosis, and Post Polycythemia Vera-Myelofibrosis whose platelet count is between 50 and 100 x109/L.

The purpose of the study is to determine the effects of treatment with the experimental drug ruxolitinib on spleen volume. The study will help determine the appropriate dosing for people with low platelets.

Study participants will receive for 24 weeks. If you are receiving benefit from treatment, further participation may continue.

Disease Status and/or Stage

Primary Myelofibrosis; Post Essential Thrombocythemia-myelofibrosis; Post Polycythemia Vera-myelofibrosis


Incyte Corporation

Key Eligibility

  • Men and women age 18 and older
  • Diagnosed with myelofibrosis (either PMF, PPV-MF or PET-MF)
  • Detailed eligibility reviewed when you contact the study team

Principal Investigator

Richard Silver, MD


Healthy Volunteers


As a healthy volunteer in a clinical trial you may make a significant contribution to the discovery of medical knowledge and new treatments that could impact people around the world.
Click here for studies seeking healthy volunteers.

Contact Us

For general inquiries, or if you need assistance finding a study, please contact:

Robert Hagerty
Subject Recruitment Manager
Tel: (646) 962-9340
[email protected]

Top of page